Women's Health - Board Chair, Small / Medium Women's Health Biotech

A board chair for a small / medium women’s health biotech company has expertise in diagnostics, gynecologic oncology, and endometriosis. This stakeholder considers research, demonstrated clinical utility / validity, (non-invasive) diagnostics, regulatory barriers, reimbursement, and limited access to care to be significant challenges in the women’s health space. They consider the highest unmet needs to be in endometriosis, pregnancy complications, fertility, and menopause and the highest precision medicine activity in the next 1-2 years to focus on endometriosis and pregnancy complications. This stakeholder noted activity from Sumitovant / Myovant, Kindbody, Proov, Mira, and Natalist. In the future, they expect several significant shifts in healthcare driven by COVID, including consumer empowerment with at-home testing, personalized medicine, wearable devices, virtual healthcare, insurance bundling, and social determinants of health.

‍